Description
An orally bioavailable broad-spectrum triazole antifungal agent; completely inhibits growth of T. rubrum, M. audouini, M. canis, and T. verrucosum, as well as some C. albicans and A. fumigatus strains and other fungi (100 μg/ml); bacteriostatic against E. coli, P. aeruginosa, S. aureus, and S. pyogenes (100 μg/ml); eliminates vaginal C. albicans candidiasis infection in 97% of rats (1%, topical); eliminates vaginal C. albicans candidiasis infection in 50% of rats (10 mg/kg, oral); decreases synthesis of 14α-desmethyl sterols and increases synthesis of methylated sterols in C. albicans (IC50 = 3 nM)
Formal name: 1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-rel-piperazine
Synonyms: (±)-Terconazole|NSC 331942|R-42470
Molecular weight: 532.5
CAS: 67915-31-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antibiotics||Product Type|Biochemicals|Antifungals|Triazoles||Product Type|Biochemicals|Small Molecule Inhibitors|Cytochrome P450||Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases||Research Area|Infectious Disease|Fungal Diseases|Aspergillosis||Research Area|Infectious Disease|Fungal Diseases|Candidiasis
